November 16, 2016 - By kentuckypostne · 0 Comments
Cancer Genetics Inc (NASDAQ:CGIX) institutional sentiment increased to 1.5 in 2016 Q2. Its up 0.87, from 0.63 in 2016Q1. The ratio improved, as 15 active investment managers increased and started new stock positions, while 10 sold and trimmed positions in Cancer Genetics Inc. The active investment managers in our partner’s database now hold: 1.58 million shares, up from 1.27 million shares in 2016Q1. Also, the number of active investment managers holding Cancer Genetics Inc in their top 10 stock positions was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 4 Increased: 9 New Position: 6.
Cancer Genetics, Inc. is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic services and products, and molecular markers. The company has a market cap of $30.22 million. The Firm develops, commercializes and provides molecular- and biomarker tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It currently has negative earnings. It has a range of disease-focused oncology testing portfolio.
About 412 shares traded hands. Cancer Genetics Inc (NASDAQ:CGIX) has declined 40.07% since April 14, 2016 and is downtrending. It has underperformed by 44.76% the S&P500.
According to Zacks Investment Research, “Cancer Genetics, Inc. operates as a diagnostics company focused on developing and commercializing proprietary genomic tests and services to improve the diagnosis, prognosis and response to treatment of cancer. The company’s tests target cancers, including hematological, urogenital, and HPV-associated cancers. It also offers non-proprietary oncology-focused tests and laboratory services that provide critical genomic information to healthcare professionals as well as biopharma and biotech. Cancer Genetics, Inc. is headquartered in Rutherford, New Jersey.”
Perkins Capital Management Inc holds 1.33% of its portfolio in Cancer Genetics Inc for 581,200 shares. Diker Management Llc owns 29,815 shares or 0.02% of their US portfolio. Moreover, Sabby Management Llc has 0.02% invested in the company for 199,580 shares. The Missouri-based Sterneck Capital Management Llc has invested 0.02% in the stock. Advisory Services Network Llc, a Georgia-based fund reported 500 shares.#img1#
Insider Transactions: Since January 1, 0001, the stock had 2 buys, and 0 selling transactions for $421,491 net activity.
Ratings analysis reveals 67% of Cancer Genetics’s analysts are positive. Out of 3 Wall Street analysts rating Cancer Genetics, 2 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $6 while the high is $8. The stock’s average target of $7 is 351.61% above today’s ($1.55) share price. CGIX was included in 3 notes of analysts from March 11, 2016. The firm earned “Buy” rating on Tuesday, March 15 by Aegis Capital. Janney Capital downgraded the shares of CGIX in a report on Friday, March 11 to “Neutral” rating. Rodman & Renshaw initiated the stock with “Buy” rating in Monday, September 26 report.
Cancer Genetics, Inc., incorporated on April 8, 1999, is engaged in the field of personalized medicine, enabling precision medicine in the field of oncology through its diagnostic services and products and molecular markers. The Firm develops, commercializes and provides molecular- and biomarker tests and services that enable physicians to personalize the clinical management of each individual patient by providing genomic information to diagnose, monitor and inform cancer treatment, and enable biopharmaceutical companies engaged in oncology trials to select candidate populations and manage adverse drug reactions by providing information regarding genomic factors influencing subject responses to therapeutics. It has a range of disease-focused oncology testing portfolio. The Company’s molecular- and biomarker diagnostic services are for three main sectors: cancer centers and hospitals, biotechnology and biopharmaceutical companies, and the research community. The Company’s services include clinical services, biopharma services and discovery services.
More important recent Cancer Genetics Inc (NASDAQ:CGIX) news were published by: Globenewswire.com which released: “Cancer Genetics, Inc. Launches Focus::Renalâ„¢, a Unique, Comprehensive and …” on November 02, 2016, also Globenewswire.com published article titled: “Cancer Genetics, Inc. to Present at the Dawson James Securities Growth Stock …”, Globenewswire.com published: “Cancer Genetics Inc. Selected by H3 Biomedicine Inc., to Provide Biomarker …” on July 18, 2016. More interesting news about Cancer Genetics Inc (NASDAQ:CGIX) was released by: Nasdaq.com and their article: “Cancer Genetics, Inc. Announces Strong Third Quarter with 68% Year Over Year …” with publication date: November 10, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.